Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Global independent private equity fund Jeito Capital has closed its second fund, Jeito II, surpassing its target of €1bn ($1.2bn), thereby establishing a significant new milestone for investment in European Biopharma.
Jeito II has invested in companies addressing conditions such as autoimmune, cardiometabolic and inflammatory diseases. Credit: SmartPhotoLab / Shutterstock.com.
Subscribe to our email newsletter
The milestone increases Jeito’s assets under management to €1.6bn, following the €534m closure of Jeito I in 2021.
Continuing the initiative set by Jeito I, Jeito II will invest in 15 to 20 clinical-stage biopharma companies, mainly in Europe, for developing breakthrough therapies targeting severe diseases with high unmet medical needs.
This fundraising enables Jeito to enhance the average size of forthcoming investments in portfolio companies to €150m, and allows them to expedite their progress towards advanced clinical development.
Jeito II has already deployed capital into companies addressing therapeutic areas such as autoimmune, cardiometabolic and inflammatory diseases, as well as obesity, oncology, and reproductive medicine.
Jeito’s investment approach emphasises high-potential companies developing breakthrough therapies.
Jeito II received support from investors in Asia, Europe, and North America, including sovereign wealth funds, corporate entities, banks, and family offices.
Jeito Capital founder and CEO Dr Rafaèle Tordjman said: “The closing of Jeito II at more than one billion euros represents a very significant milestone for our business. This record fundraising is a collective success, reflecting the dedication and expertise of the entire Jeito team, the talent of its portfolio companies’ managers and the trust of our investors.
“We would like to thank them all for their hard work, dedication and support. It is also a strong signal for the European Biopharma ecosystem, demonstrating the growing conviction that European companies can drive major therapeutic innovation and significant economic benefits with the appropriate access to financial and strategic resources.”
